Figure 6. JAK inhibition reduces age-related fat loss in mice.
Twenty-two-month old male mice were treated with vehicle (CON) or ruxolitinib (INCB) for 8 weeks. Fat mass (a) and lean mass (b) were measured by MRI along with body weight (c) before treatment, as well as 1 month and 2 months after treatment. The percent changes relative to baseline are shown for fat mass (d), lean mass (e), and body weight (f). Results (N=9) are expressed as mean ± s.e.m. *p<0.05. Two-tailed Student's t tests were used to determine statistical significance.
DOI: http://dx.doi.org/10.7554/eLife.12997.017
Figure 6—source data 1. JAK inhibition reduces age-related fat loss in mice.
elife-12997-fig6-data1.xlsx (13.6KB, xlsx)
DOI: 10.7554/eLife.12997.018
Figure 6—figure supplement 1. JAK inhibition did not affect metabolic rate or food intake in aged mice.
Twenty-two-month old male mice were monitored using CLAMS before and after 8 weeks of vehicle (CON) or ruxolitinib (INCB) treatment. (a) Metabolic rate and (b) food intake (N=7) are expressed as mean ± s.e.m. Two-tailed Student's t tests were used to determine statistical significance.
Figure 6—figure supplement 2. JAK inhibition had less impact on body composition and adipogenesis in 8-month old mice compared to 22-month old mice.
Eight-month old male mice were treated with vehicle (Y CON) or ruxolitinib (Y INCB) for 8 weeks. (a) Fat mass, lean mass, and body weight were measured before and one month after treatment. The percent changes relative to baseline (N=6) are expressed as mean ± s.e.m. (b) RNA from WAT was isolated and real-time PCR was performed. Results (N=6) are expressed as mean ± s.e.m. (c) WAT was collected from 8-month old (Young) and 22-month old mice (Old). RNA was isolated and real-time PCR was performed. Results (N=6 for Young, N=8 for Old) are expressed as mean ± s.e.m. *p<0.05. Two-tailed Student's t tests were used to determine statistical significance.